 |
27 Diseases |  |
27 Trials |
|
27 Trials |  |
3795 News |  |
| «12...1011121314151617181920...4546» |
- || dimethyl fumarate / Generic mfg.
Biogen’s contingency plan to keep Tecfidera generics at bay has fallen flat https://t.co/cB4bxcut1e (Twitter) - Mar 17, 2022
- | glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Observational data, Retrospective data, Journal: Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions. (Pubmed Central) - Mar 15, 2022
We have demonstrated that a specific disease modifying therapy, DMF, decreases glial activity in chronic active lesions. Susceptibility changes in rim lesions provide an in vivo biomarker for the effect of DMF on microglial activity.
- ||| Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal, Adverse events, Adverse drug reaction: Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database. (Pubmed Central) - Mar 15, 2022
All national publicly-available aggregated ADR reports recorded from 2002 to 2020 into the Reports of Adverse Reactions of Medicines (RAM) system and all complete Sicilian data reported into the Italian spontaneous reporting system (SRS) database having as suspected drugs interferon β-1a (IFN β-1a), interferon β-1b (IFN β-1b), peginterferon β-1a (PEG-IFN β-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected...The reporting of drugs-related ADRs in MS were mostly reported in the literature, but some unknown ADRs were also found. However, further studies are necessary to increase the awareness about the safety profiles of new drugs on the market.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. (Pubmed Central) - Mar 12, 2022
P=N/A
Interim results from this large registry indicate that early DMF exposure was not significantly associated with adverse pregnancy outcomes. Outcomes are consistent with previous smaller reports and with the general population.
- ||| Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal, Adverse events: Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: a disproportionality analysis using US Food and Drug Administration Adverse Event Reporting System (FAERS) database. (Pubmed Central) - Mar 11, 2022
No safety signal for increased cancer-risk was detected among the approved DMTs, although more robust evidence is needed. A potential safety signal detected in the sensitivity analysis concerning Interferon-beta1a, Alemtuzumab, requires further evaluation with more robust evidence.
- | dimethyl fumarate / Generic mfg.
Journal: Familial multiple sclerosis in patients with Von Hippel-Lindau disease. (Pubmed Central) - Mar 11, 2022
The VHL gene is known to be the primary regulator of Nrf2, the well-established target of the FDA-approved therapeutic dimethyl fumarate. These cases provide support for further studies to determine whether VHLD pathway related genes represent a novel genetic link in multiple sclerosis.
- Profile of Patients with Multiple Sclerosis on Oral Disease-Modifying Therapies While Enrolled in North American Registry for Care and Research in Multiple Sclerosis (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1730;
Our results suggest that real-world patients on oral DMTs are similar to MS patients overall. As MS registries are growing, capturing high-quality, long-term data is increasingly important as more treatment options become available.
- Lemtrada (alemtuzumab) / Sanofi
A Cost-Effectiveness Analysis of Biologic Compared with Chemical Disease Modifying Drugs in Treating Multiple Sclerosis in US (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1042;
Ocrelizumab is most cost-effective, followed by Alemtuzumab, Natalizumab, Dimethyl Fumarate, and Fingolimod. Ocrelizumab should be prioritized in clinical practice with economic considerations.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg., fingolimod / Generic mfg.
Factors Associated with Prescribing of Teriflunomide and Dimethyl Fumarate Versus Fingolimod in Multiple Sclerosis (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_424;
The study found that DMF is the most prescribed oral DMA for MS. Patients’ predisposing (age group and region), enabling (insurance), and need factors (comorbidities and neurologist consultation) influenced the selection of specific DMA.
- Comparative Adherence Trajectories across Oral Disease-Modifying Agents in Multiple Sclerosis () - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_14;
Teriflunomide and dimethyl fumarate were associated with poorer adherence trajectories than fingolimod. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs for the management of MS.
- Mavenclad (cladribine) / EMD Serono
Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3903;
For all three pairwise comparisons, relapse and discontinuation outcomes significantly favoured CladT over other oral DMTs. Future analyses with longer follow-up comparing disability progression events are warranted.
- Temporal Trends in Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated With Natalizumab, Ocrelizumab or Fumarates (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3888;
T-cell responses were comparable among all three treatment cohorts. Two months after the second vaccine, the serological responses decreased by 45-79%.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Updated Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3763;
Two months after the second vaccine, the serological responses decreased by 45-79%. In this analysis of >1,000 patients treated with DRF in real-world clinical practice, overall persistence at 16 months was high, treatment discontinuation due to GI AEs was low, and patients were highly adherent to therapy. Study Supported by: Biogen
- Lemtrada (alemtuzumab) / Sanofi
Two-Year Interim Analysis of the TREAT-MS Alemtuzumab Study in Germany Differentiated by Direct Pretreatment (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3762;
Hereof, 17.0% (n=84) were treatment-naïve and 83% received the following last previous therapy prior to alemtuzumab: fingolimod (28.5%, n=141), natalizumab (21.1%, n=104), basic injectables (glatiramer acetate or interferon-beta; 20.6%, n=102), or basic orals (dimethyl fumarate or teriflunomide; 12.8%, n=63)... These interim results indicate that alemtuzumab shows good real-world effectiveness and safety across patient subgroups with different pretreatment history but less pronounced effects after fingolimod pretreatment.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Diroximel Fumarate (DRF) Has High Rates of Real-World Adherence and Persistence in Patients with Multiple Sclerosis (MS): Retrospective Claims Analysis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3761;
Adherence rates were high throughout time on treatment for patients on DRF. Outcomes for DRF are consistent with or higher than those for other DMTs observed in the same treatment period.Study Supported by: Biogen
- Fumaderm (dimethyl fumarate) / Biogen
Retrospective Evaluation of De-Escalation from Anti-CD20 Therapies to Fumarates as a Treatment Approach (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3751;
Patients had a variety of motivations for switching to DMF from anti-CD20s. Additional patients will be presented.
- Fumaderm (dimethyl fumarate) / Biogen
Dimethyl Fumarate Demonstrates Treatment Effectiveness in Patients One Year After Switching From Teriflunomide (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3750;
P=N/A, P4
DMF is an effective therapeutic strategy for patients previously treated with teriflunomide regardless of if switching for efficacy or non-efficacy reasons. Study Supported by: Biogen
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
COVID19 infections in patients with Multiple Sclerosis (MS) on Various treatments at Kaiser Permanent Mid-Atlantic States (KPMAS) (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3673;
We found that the rates of COVID19 infection in patients with MS in the BDT group were not out of proportion when compared to those on other treatments for MS. The poor outcomes were more likely to be related to underlying comorbidities.
- Mayzent (siponimod) / Novartis
Safety and Tolerability of Conversion to Siponimod With and Without Titration in Patients with Advancing Forms of Relapsing Multiple Sclerosis: Interim Results of the Phase 3b EXCHANGE Study (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3615;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety/tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- Fumaderm (dimethyl fumarate) / Biogen
Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3614;
P=N/A
Results from the 6-year interim analysis demonstrate the safety profile in this ongoing, real-world observational study is consistent with the known profile of DMF. Similarly, relapse rates were low and both ARR and PROs remained stable over time indicating sustained effectiveness for patients who remain on DMF treatment over 6 years.Support:Biogen
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3610;
P3
At 2 years, safety, clinical, and radiological measures were reduced from baseline, supporting DRF as an effective treatment option and consistent with the known benefit-risk profile for DMF. The low rate of treatment discontinuation over 2 years suggests DRF is a well-tolerated treatment option for RRMS.Study Supported by: Biogen
- Mavenclad (cladribine) / EMD Serono
Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3551;
In this sample from our RWC, dose adjustment during initial Clad-IRT course(s) may have contributed to resuming disease activity. Clinical monitoring and mechanistic studies continue to address this question.
- dimethyl fumarate / Generic mfg.
Clinical-pathological correlation of progressive solitary sclerosis: a case report (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3549;
Clinical monitoring and mechanistic studies continue to address this question. Despite trials of dimethyl fumarate, and then rituximab infusions, he progressed to requiring a walker in 2013...To our knowledge, this is the first reported case of progressive solitary sclerosis fitting the proposed clinical phenotype in addition to pathological confirmation of MS-like lesions, but within a single lesion of the brain and spinal cord.
- dimethyl fumarate / Generic mfg.
Association of Epigenetic Biomarkers of Neoplasia with Multiple Sclerosis in an Underrepresented Minority Population (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3049;
This work also suggests that parallel analyses can be performed in the presence and absence of corrections for immune therapies. These results may be of specific relevance in the regulation of disease pathogenesis in underrepresented minority populations.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., fingolimod / Generic mfg.
miRNA as biomarkers of NEDA-3 in multiple sclerosis patients treated with fingolimod, glatiramer acetate and dimethyl-fumarate: Preliminary results (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3031;
These results suggest that miRNA could be a potential biomarker of treatment response. Further validation and research need to be performed to better understand the role of miRNA as response biomarkers.
- Fumaderm (dimethyl fumarate) / Biogen
Predicting Treatment Response with MRI-Based Subtyping in Relapsing and Secondary Progressive MS (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3001;
NTZ and DMF reduced inflammatory disease activity in all SuStaIn subtypes with no significant differences in treatment response. SuStaIn MS subtyping did not discriminate responder heterogeneity as assessed by new lesion formation in these NTZ and DMF trials.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Covid19 in Multiple Sclerosis Patients in Dubai : Observational Study (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2876;
A higher EDSS score, progressive disease, use of rituximab, and ocrelizumab(antiCD20 therapy) were associated with the mortality encountered. Age, sex, smoking history, and duration of MS were not independent risk factors for increased severity or adverse COVID-19 disease outcomes.
- evobrutinib (M2951) / EMD Serono
Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor in Relapsing Multiple Sclerosis Over 2.5 Years of The Open-Label Extension to a Phase II Trial (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2792;
P2
Age, sex, smoking history, and duration of MS were not independent risk factors for increased severity or adverse COVID-19 disease outcomes. Evobrutinib safety and efficacy data over 2.5 years in pwRMS continue to show acceptable tolerability, with no new safety signals, and maintained efficacy.
- dimethyl fumarate / Generic mfg.
Trajectories of disability and relapse-rate in naïve patients on oral drugs: results from the Italian Multiple Sclerosis Register (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2429;
Design/ This retrospective observational cohort included treatment-naive patients from the Italian MS registry, starting fingolimod (FIN), teriflunomide (TER) or dimethyl fumarate (DMF), followed-up for 5 years, with ≥1 EDSS per year... In our real-life cohort, the three oral DMTs showed a similar long-term effect on disability progression, while FIN proved to be more effective on relapse-rate.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Patterns of Healthcare Utilization and Expenditure among People with Multiple Sclerosis in the Age of Disease-Modifying Therapy: An Analysis of Claim Data from a Commercially Insured Population in the United States, 2010-2019 (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2426;
Design/ In a retrospective analysis using claims data from a commercially insured population (2010-2019), we assigned patients to treatment arms based on DMTs received during the coverage period: no DMT (ND), high-efficacy (HE) (alemtuzumab, B-cell depletion, cladribine, natalizumab), and standard-efficacy (SE) DMT (dimethyl fumarate, glatiramer acetate, interferon-beta, sphingosine-1-phosphate receptor modulator, teriflunomide)... DMT cost is a key driver of the healthcare expenditure in MS, highlighting the need for prospective comparative studies towards value-based medicine.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Treatment Patterns Among Newly Diagnosed Patients With Multiple Sclerosis by Race and Ethnicity () - Mar 6, 2022 - Abstract #AAN2022AAN_2392;
Glatiramer acetate was the most frequently initiated first-line DMT across all races/ethnicities (32%), followed by dimethyl fumarate (18%) and ocrelizumab (17%). Non-Hispanic Black and Hispanic patients were frequently treated with glatiramer acetate as the first-line treatment, and few initiated any high-efficacy DMT in the two years after diagnosis, despite the increased risk of highly active disease.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Serum NfL and GFAP biomarker analysis in early high versus low efficacy DMT paradigms for MS ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_2055;
In cohort A, with pretreatment levels, sNFL and sGFAP trended to decrease more rapidly in HEET compared to LEET. Thus, pretreatment biomarkers followed longitudinally may inform prognostication and monitoring of the HEET or LEET approach; additional randomized studies are necessary.
- dimethyl fumarate / Generic mfg.
Impact of Covid-19: Preserving Services for Patients with Multiple Sclerosis during a Global Pandemic. ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1859;
Whilst most patients experienced normal standard care, Covid-19 has impacted service provision for some pwMS, with delays reported across a multi-faceted service. The downstream effects of this may be seen moving beyond the pandemic.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Immune checkpoint inhibitors and multiple sclerosis ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1855;
However, patients in this cohort were older and had benign or inactive MS. Larger studies are needed in MS patients on ICPIs to further understand the risk of MS relapses and disease progression.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1752;
Ofatumumab was dominant (more efficacy, lower costs) over first-line DMTs teriflunomide, interferons, dimethyl fumarate, and ocrelizumab, and resulted in incremental cost-effectiveness ratios (ICERs) of $24,177 Canadian dollars per quality-adjusted life-years (QALYs) gained versus glatiramer acetate and $28,034 versus BSC... Ofatumumab is cost effective against all comparators and dominant against all currently approved and reimbursed first-line DMTs for RRMS, except glatiramer acetate.
- Mavenclad (cladribine) / EMD Serono
Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1733;
At datacut, CLICK-MS and MASTER-2 have enrolled patients switching from a variety of DMTs. TEAEs reported were low in frequency and severity, and did not lead to treatment discontinuation.
- Mavenclad (cladribine) / EMD Serono
Impact of Multiple Sclerosis Disease-Modifying Therapies on Effectiveness of SARS-Cov-2 Vaccines: A Longitudinal Total Population Study of National Health Service (NHS) England () - Mar 6, 2022 - Abstract #AAN2022AAN_1489;
The changes associated with other DMTs are less clear. Further analysis of data collected longitudinally over a longer period will reveal their impact on the effectiveness of SARS-CoV-2 vaccines.
- Lemtrada (alemtuzumab) / Sanofi, Spikevax (elasomeran) / Moderna, Takeda
Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review and meta-analysis () - Mar 6, 2022 - Abstract #AAN2022AAN_1488;
Humoral responses appear to be blunted in S1PM and anti-CD20 treatments; however, the majority develop cellular responses. Further investigation into how DMT affects immune response are needed.
- ||| Lemtrada (alemtuzumab) / Sanofi
Journal, Adverse events: Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. (Pubmed Central) - Mar 4, 2022
P
All consecutive reports of DMTs prescribed to pwMS (alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, interferon-β, natalizumab, ocrelizumab, and teriflunomide), and their serious adverse event cases were eligible, excluding those reporting immunosuppressant DMTs used as anticancer therapies...A close and regular cancer screening in pwMS treated with natalizumab, interferon-β, dimethyl fumarate, and fingolimod may be warranted, even for persons at a younger age. Trial Registration NCT04237337.
- || dimethyl fumarate / Generic mfg.
Clinical, Journal: Unexpected improvements of Parkinson's symptoms in a psoriatic patient during dimethyl fumarate therapy. (Pubmed Central) - Mar 3, 2022
Trial Registration NCT04237337. No abstract available
- || dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
Clinical, Journal, Real-world evidence: Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. (Pubmed Central) - Mar 3, 2022
No abstract available TERI and DMF have similar effectiveness and rate of discontinuation when employed as first therapeutic choice in RRMS patients.
- | dimethyl fumarate / Generic mfg.
Journal, Lymphopenia: Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. (Pubmed Central) - Mar 3, 2022
Mean times to persistent moderate and severe lymphopenia were 10.6 months and 25.5 months respectively. Increased age was a predictor for persistent lymphopenia (B = 0.071, p = 0.004) while sex, and previous DMT were not.
- | dimethyl fumarate / Generic mfg.
Journal: Myoglobin promotes macrophage polarization to M1 type and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway in CS-AKI. (Pubmed Central) - Mar 3, 2022
In addition, pyroptosis inhibitor DMF not only alleviated kidney injury of CS-AKI mice but also inhibited macrophage polarization to M1 phenotype and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway. Our research found that myoglobin promotes macrophage polarization to M1 type and pyroptosis via the RIG-I/Caspase1/GSDMD signaling pathway in CS-AKI.
- || dimethyl fumarate / Generic mfg.
Clinical, Journal: Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. (Pubmed Central) - Feb 26, 2022
There was no significant improvement in the primary endpoint. The trial provides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS.
- | glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Journal, IO biomarker: Multiple sclerosis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. (Pubmed Central) - Feb 26, 2022
The trial provides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS. These findings from a large MS cohort exposed to a wide spectrum of MS immunotherapies have important implications for treatment-specific COVID-19 clinical guidelines.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America. (Pubmed Central) - Feb 23, 2022
The most common challenge and barrier identified was the cost of medications. The present study allows an understanding of the delivery of care for MS and NMOSD in the region.
- || dimethyl fumarate / Generic mfg.
I got told that 9 years ago as I didn’t have lesions in my spine. Now I do and have persistent Lehmittes sign 9 months later, and finally on Tecfidera. When seeing a new specialist I got a weird eye as to why I wasn’t on them already. Id he et a second opinion if I was you. (Twitter) - Feb 20, 2022
- Lemtrada (alemtuzumab) / Sanofi
Breast Cancer in Multiple Sclerosis Patients Treated with Disease Modifying Therapies (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_550;
Further examination of odds ratios showed additional increases with INFb1a and NAT. The lowest proportions were reported with ALE and FIN; however, further examination of odds ratios showed decreases with INFb1b, GA, TER, and ALE.
- dimethyl fumarate / Generic mfg.
Effect of the disease modifying agents on the disease progression, radiological profile and subcortical grey matter volume in Multiple Sclerosis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_530;
100% on NTZ & 90% patients on RTX had decrease in MRI lesions are more efficacious compared with DMF. SCGMA (thalamus>pallidum) is more with RTX than NTZ.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
Use of Disease-Modifying Drugs in Multiple Sclerosis (Virtual Poster Hall) - Feb 20, 2022 - Abstract #ACTRIMSForum2022ACTRIMS_Forum_484;
The most used DMD were Glatiramer Acetate (22.13%), Dimethyl Fumarate (20.49%), and Interferon Beta1a (17.21%), with Interferon Beta1a being the most used as a first choice (36.2%)... We concluded that DMD switches were related to the progression of cases, reinforcing the importance of an optimized decision of treatment, reducing the accumulation of disabilities, and delaying the progression of the disease.